Segment 2: Overview of Results from EMILIA and MARIANNE Trials

In this clip, Dr. Swain and Dr. Newcomer discuss the results from the EMILIA trial. Dr. Swain notes that the survival benefit with the use of TDM-1 was five months. “That’s probably one of the best responses we have seen in breast cancer in almost a decade,” said Dr. Newcomer. Panelists also discuss the FDA’s recent granting of priority review to pertuzumab for use in an earlier line of therapy based on the NEOSPHERE study and TRYPHAENA studies.